Float Short %

25.73

Margin Of Safety %

Put/Call OI Ratio

0.51

EPS Next Q Diff

0.08

EPS Last/This Y

0.02

EPS This/Next Y

1.19

Price

10.19

Target Price

35.75

Analyst Recom

1.23

Performance Q

-32.11

Relative Volume

0.99

Beta

0.78

Ticker: SNDX

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-04-14	SNDX	11.26	0.61	0.07	29594
2025-04-15	SNDX	11.34	0.60	0.00	29918
2025-04-16	SNDX	11.06	0.60	3.91	29922
2025-04-17	SNDX	11.57	0.53	0.01	28710
2025-04-18	SNDX	11.54	0.53	0.01	28710
2025-04-21	SNDX	11.95	0.63	0.00	24205
2025-04-22	SNDX	12.92	0.56	0.48	25868
2025-04-23	SNDX	13	0.58	0.00	30988
2025-04-24	SNDX	13.31	0.57	2.00	31483
2025-04-25	SNDX	13.33	0.56607809002736	1.8333333333333	31486
2025-04-28	SNDX	13.42	0.57093770230566	0.014925373134328	31546
2025-04-29	SNDX	13.69	0.57	3.62	31486
2025-04-30	SNDX	14.12	0.59	0.05	31731
2025-05-01	SNDX	13.74	0.58	0.00	31923
2025-05-02	SNDX	13.7	0.47	0.92	37255
2025-05-05	SNDX	13.55	0.48	0.01	37515
2025-05-06	SNDX	10.6	0.46	0.24	38655
2025-05-07	SNDX	9.97	0.51	0.04	37987
2025-05-08	SNDX	10.99	0.52	0.12	37507
2025-05-09	SNDX	10.69	0.50	0.38	39550
2025-05-12	SNDX	10.99	0.49	3.89	40735
2025-05-13	SNDX	10.19	0.51	0.44	41562
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-04-14	SNDX	11.24	-46.1	55.1	-3.81
2025-04-15	SNDX	11.33	-51.0	54.7	-3.81
2025-04-16	SNDX	11.05	-51.0	66.1	-3.81
2025-04-17	SNDX	11.54	-51.0	42.6	-3.81
2025-04-18	SNDX	11.54	-51.0	57.7	-3.81
2025-04-21	SNDX	11.94	-51.0	46.1	-3.81
2025-04-22	SNDX	12.92	-51.0	29.9	-3.81
2025-04-23	SNDX	13.00	-51.0	55.6	-3.81
2025-04-24	SNDX	13.31	-51.0	49.8	-3.81
2025-04-25	SNDX	13.33	-51.0	56.8	-3.81
2025-04-28	SNDX	13.42	-51.0	55.5	-3.81
2025-04-29	SNDX	13.70	-51.0	50.9	-3.81
2025-04-30	SNDX	14.15	-51.0	47.1	-3.81
2025-05-01	SNDX	13.82	-51.0	64.4	-3.81
2025-05-02	SNDX	13.73	-51.0	59.6	-3.81
2025-05-05	SNDX	13.57	-49.8	61.3	-3.78
2025-05-06	SNDX	10.61	-49.8	127.7	-3.78
2025-05-07	SNDX	9.99	-49.8	93.2	-3.78
2025-05-08	SNDX	10.99	-22.2	-70.4	-3.78
2025-05-09	SNDX	10.69	-22.2	26.7	-3.70
2025-05-12	SNDX	10.99	-22.2	-11.5	-3.70
2025-05-13	SNDX	10.19	-22.2	56.8	-3.70
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-04-14	SNDX	-1.55	12.66	23.00
2025-04-15	SNDX	-1.55	12.66	23.00
2025-04-16	SNDX	-1.55	12.66	23.00
2025-04-17	SNDX	-1.55	12.66	23.00
2025-04-18	SNDX	-1.55	12.66	23.00
2025-04-21	SNDX	-1.55	10.11	23.00
2025-04-22	SNDX	-1.56	10.11	23.00
2025-04-23	SNDX	-1.56	10.11	23.00
2025-04-24	SNDX	-1.56	10.11	23.00
2025-04-25	SNDX	-1.56	10.11	23.00
2025-04-28	SNDX	-1.56	5.55	25.15
2025-04-29	SNDX	-1.56	5.55	25.15
2025-04-30	SNDX	-1.56	5.55	25.15
2025-05-01	SNDX	-1.56	5.55	25.15
2025-05-02	SNDX	-1.56	5.55	25.15
2025-05-05	SNDX	-1.56	-1.29	25.15
2025-05-06	SNDX	-1.56	-1.29	25.15
2025-05-07	SNDX	-1.56	-1.29	25.15
2025-05-08	SNDX	-1.56	-1.29	25.15
2025-05-09	SNDX	-1.56	-1.29	25.15
2025-05-12	SNDX	-1.56	1.15	25.73
2025-05-13	SNDX	-1.56	1.15	25.73
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.98

Avg. EPS Est. Current Quarter

-0.98

Avg. EPS Est. Next Quarter

-0.9

Insider Transactions

-1.56

Institutional Transactions

1.15

Beta

0.78

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

65.9

Max Drawdown 5-Year %

-65.5

Target Price

35.75

P/E

Forward P/E

PEG

P/S

20.06

P/B

4.08

P/Free Cash Flow

EPS

-3.87

Average EPS Est. Cur. Y

-3.7

EPS Next Y. (Est.)

-2.5

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-757.52

Relative Volume

0.99

Return on Equity vs Sector %

-177.7

Return on Equity vs Industry %

-160.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.09

EBIT Estimation

56.8

Syndax Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 270

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

stock quote shares SNDX – Syndax Pharmaceuticals, Inc. Stock Price stock today

news today SNDX – Syndax Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch SNDX – Syndax Pharmaceuticals, Inc. yahoo finance google finance

stock history SNDX – Syndax Pharmaceuticals, Inc. invest stock market

stock prices SNDX premarket after hours

ticker SNDX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: SNDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y